ArticleCancer reports (Hoboken, N.J.)2026
Diabetes and Cancer-Specific Survival: A Nationwide Population-Based Cohort Study Across Multiple Cancer Sites.
Article in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundCancer patients with concurrent diabetes generally show poorer survival compared with nondiabetic patients.
aimsWe examined the relationship between Type 2 diabetes and cancer-specific survival in the 13 most common cancer sites within a large population-based cohort in Finland. We hypothesized that survival would be lower among patients with diabetes across cancer types. METHODS AND
resultsThe cohort, derived from the Finnish CARING Project, included 49 799 incident cancer cases: 25 899 in patients with diabetes and 23 900 in nondiabetic patients. The mean age at diagnosis was 72.2 years, and 40.9% were women. During a mean follow-up of 3.8 years (188 329 person-years), 13 602 cancer deaths occurred. The impact of diabetes on prognosis varied by cancer type. Survival was substantially lower for stomach, endometrial, and lympho-hematological cancers, and slightly lower for colon and breast cancer. Conversely, patients with diabetes had higher survival for liver and rectal cancer. No notable differences were observed for pancreatic, bladder, kidney, prostate, lung, or nonmelanoma skin cancer.
conclusionFuture studies should focus on the biological and metabolic factors influencing cancer survival in patients with diabetes and on how treatment strategies can be optimized to reduce excess cancer mortality in this patient group.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.